Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

15.12. Referanser

Abruzzese, E., Mauro, M., Apperley, J., & Chelysheva, E. (2020). Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Therapeutic advances in hematology, 11, 2040620720966120. https://doi.org/10.1177/2040620720966120

Aggarwal, S., van de Loosdrecht, A. A., Alhan, C., Ossenkoppele, G. J., Westers, T. M., & Bontkes, H. J. (2011). Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. British Journal of Haematology, 153(5), 568-581. https://doi.org/10.1111/j.1365-2141.2011.08683.x

Almond, L. M., Charalampakis, M., Ford, S. J., Gourevitch, D., & Desai, A. (2017). Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clinical lymphoma, myeloma & leukemia, 17(5), 263-267. https://doi.org/10.1016/j.clml.2017.02.027

Aloe Spiriti, M., Latagliata, R., Avvisati, G., Battistel, V., Montefusco, E., Spadea, A., & Petti, M. C. (1993). Erythropoietin treatment of idiopathic myelofibrosis. Haematologica, 78(6), 371-373.

Alvarez-Larrán, A., Pereira, A., Guglielmelli, P., Hernández-Boluda, J. C., Arellano-Rodrigo, E., Ferrer-Marin, F., . . . Besses, C. (2016). Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 101(8), 926-931. https://doi.org/10.3324/haematol.2016.146654

Andersen, C. L., Andreasson, B., Hasselbalch, H., Hultcrantz, M., Knutsen, H., Lindgren, M., . . . Larsen, T. S. (2013). Nordic guidelines on the diagnosis and treatment of patients with Myeloproliferative Neoplasms (rev. utg.). Stockholm: Nordic MPD study group.

Apperley, J. F. (2007). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology, 8(11), 1018-1029. https://doi.org/10.1016/S1470-2045(07)70342-X

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., . . . Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. https://doi.org/10.1182/blood-2016-03-643544

Archimbaud, E., Thomas, X., Leblond, V., Michallet, M., Fenaux, P., Cordonnier, C., . . . Travade, P. (1995). Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. Journal of Clinical Oncology, 13(1), 11-18. https://doi.org/10.1200/jco.1995.13.1.11

Armand, P., Kim, H. T., Virtanen, J. M., Parkkola, R. K., Itälä-Remes, M. A., Majhail, N. S., . . . Wermke, M. (2014). Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 20(8), 1248-1251. https://doi.org/10.1016/j.bbmt.2014.04.024

Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., . . . Hehlmann, R. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122(6), 872-884. https://doi.org/10.1182/blood-2013-05-501569

Balsat, M., Renneville, A., Thomas, X., de Botton, S., Caillot, D., Marceau, A., . . . Boissel, N. (2017). Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 35(2), 185-193. https://doi.org/10.1200/jco.2016.67.1875

Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., . . . Tefferi, A. (2011). Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29(6), 761-770. https://doi.org/10.1200/JCO.2010.31.8436

Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., . . . Barbui, T. (2009). Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113(20), 4829-4833. https://doi.org/10.1182/blood-2008-09-176818

Baz, R. C., Martin, T. G., 3rd, Lin, H. Y., Zhao, X., Shain, K. H., Cho, H. J., . . . Jagannath, S. (2016). Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood, 127(21), 2561-2568. https://doi.org/10.1182/blood-2015-11-682518

Bazarbachi, A., Bug, G., Baron, F., Brissot, E., Ciceri, F., Dalle, I. A., . . . Mohty, M. (2020). Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 105(6), 1507-1516. https://doi.org/10.3324/haematol.2019.243410

Beck, J., Schwarzer, A., Glaser, D., Mugge, L. O., Uhlig, J., Heyn, S., . . . Ponisch, W. (2017). Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). Journal of cancer research and clinical oncology, 143(12), 2545-2553. https://doi.org/10.1007/s00432-017-2504-5

Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., . . . Facon, T. (2014). Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. The New England journal of medicine, 371(10), 906-917. https://doi.org/10.1056/NEJMoa1402551

Bene, M. C., Nebe, T., Bettelheim, P., Buldini, B., Bumbea, H., Kern, W., . . . Porwit, A. (2011). Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia, 25(4), 567-574. https://doi.org/10.1038/leu.2010.312

Bertoli, S., Bérard, E., Huguet, F., Huynh, A., Tavitian, S., Vergez, F., . . . Recher, C. (2013). Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood, 121(14), 2618-2626. https://doi.org/10.1182/blood-2012-09-454553

Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., . . . Gremy, F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48(1), 198-206. https://pubmed.ncbi.nlm.nih.gov/7237385/

Birgegård, G., Besses, C., Griesshammer, M., Gugliotta, L., Harrison, C. N., Hamdani, M., . . . Kiladjian, J. J. (2018). Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica, 103(1), 51-60. https://doi.org/10.3324/haematol.2017.174672

Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., . . . Hughes, T. P. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 33(8), 1835-1850. https://doi.org/10.1038/s41375-019-0512-y

Breems, D. A., Van Putten, W. L., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E., Verdonck, L. F., . . . Lowenberg, B. (2005). Prognostic index for adult patients with acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 23(9), 1969-1978. https://doi.org/10.1200/jco.2005.06.027

Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., . . . Palumbo, A. (2014). Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood, 124(1), 63-69. https://doi.org/10.1182/blood-2014-03-563759

Burke, P. W., Hoelzer, D., Park, J. H., Schmiegelow, K., & Douer, D. (2020). Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion. ESMO Open, 5(5). https://doi.org/10.1136/esmoopen-2020-000858

Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007). A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109(6), 1114-1124. https://doi.org/10.1002/cncr.22496

Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., . . . Grimwade, D. (2015a). Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology, 16(13), 1295-1305. https://doi.org/10.1016/s1470-2045(15)00193-x

Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., . . . Clark, R. E. (2015b). A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 125(25), 3878-3885. https://doi.org/10.1182/blood-2015-01-623447

Bustin, S. A., Beaulieu, J. F., Huggett, J., Jaggi, R., Kibenge, F. S., Olsvik, P. A., . . . Toegel, S. (2010). MIQE precis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC molecular biology, 11, 74. https://doi.org/10.1186/1471-2199-11-74

Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., . . . O'Brien, S. (2013). Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England journal of medicine, 369(1), 32-42. https://doi.org/10.1056/NEJMoa1215637

Castillo, J. J., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., . . . Kastritis, E. (2020a). Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. The Lancet. Haematology, 7(11), e827-e837. https://doi.org/10.1016/s2352-3026(20)30224-6

Castillo, J. J., Gustine, J. N., Keezer, A., Meid, K., Flynn, C. A., Dubeau, T. E., . . . Treon, S. P. (2020b). Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. American journal of hematology, 95(4), 372-378. https://doi.org/10.1002/ajh.25712

Castillo, J. J., Itchaki, G., Paludo, J., Varettoni, M., Buske, C., Eyre, T. A., . . . Treon, S. P. (2019a). Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood, 133(4), 299-305. https://doi.org/10.1182/blood-2018-10-879593

Castillo, J. J., Xu, L., Gustine, J. N., Keezer, A., Meid, K., Dubeau, T. E., . . . Treon, S. P. (2019b). CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 187(3), 356-363. https://doi.org/10.1111/bjh.16088

Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R. F., . . . Ncri Chronic Lymphocytic Leukaemia Working Group. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370(9583), 230-239. https://doi.org/10.1016/S0140-6736(07)61125-8

Cavo, M., & et al. Upublisert.

Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., . . . Sonneveld, P. (2020). Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. The Lancet. Haematology. https://doi.org/10.1016/s2352-3026(20)30099-5

Cervantes, F., Alvarez-Larrán, A., Domingo, A., Arellano-Rodrigo, E., & Montserrat, E. (2005). Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. British Journal of Haematology, 129(6), 771-775. https://doi.org/10.1111/j.1365-2141.2005.05524.x

Cervantes, F., Alvarez-Larrán, A., Hernández-Boluda, J. C., Sureda, A., Granell, M., Vallansot, R., . . . Montserrat, E. (2006). Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. British Journal of Haematology, 134(2), 184-186. https://doi.org/10.1111/j.1365-2141.2006.06142.x

Cervantes, F., Alvarez-Larrán, A., Hernández-Boluda, J. C., Sureda, A., Torrebadell, M., & Montserrat, E. (2004). Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology, 127(4), 399-403. https://doi.org/10.1111/j.1365-2141.2004.05229.x

Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., . . . Tefferi, A. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113(13), 2895-2901. https://doi.org/10.1182/blood-2008-07-170449

Cervantes, F., Hernández-Boluda, J. C., Alvarez, A., Nadal, E., & Montserrat, E. (2000). Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica, 85(6), 595-599.

Chalandon, Y., Thomas, X., Hayette, S., Cayuela, J. M., Abbal, C., Huguet, F., . . . Group for Research on Adult Acute Lymphoblastic Leukemia. (2015). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood, 125(24), 3711-3719. https://doi.org/10.1182/blood-2015-02-627935

Chang, C. K., Zhao, Y. S., Xu, F., Guo, J., Zhang, Z., He, Q., . . . Li, X. (2017). TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. British Journal of Haematology, 176(4), 600-608. https://doi.org/10.1111/bjh.14455

Chapel, H., Dicato, M., Gamm, H., Brennan, V., Ries, F., Bunch, S. C., & Lee, M. (1994). Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: A comparison of two dose regimes. British Journal of Haematology, 88(1), 209-212. https://doi.org/10.1111/j.1365-2141.1994.tb05002.x

Chari, A., Cho, H. J., Dhadwal, A., Morgan, G., La, L., Zarychta, K., . . . Parekh, S. (2017a). A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood advances, 1(19), 1575-1583. https://doi.org/10.1182/bloodadvances.2017007427

Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., . . . Lonial, S. (2017b). Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood, 130(8), 974-981. https://doi.org/10.1182/blood-2017-05-785246

Charles, N. J., & Boyer, D. F. (2017). Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls. Archives of pathology & laboratory medicine, 141(11), 1462-1468. https://doi.org/10.5858/arpa.2017-0218-RA

Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., O'Brien, S., & Rai, K. R. (1996). National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87(12), 4990-4997.

Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., . . . Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108(2), 419-425. https://doi.org/10.1182/blood-2005-10-4149

Cibeira, M. T., Sanchorawala, V., Seldin, D. C., Quillen, K., Berk, J. L., Dember, L. M., . . . Skinner, M. (2011). Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 118(16), 4346-4352. https://doi.org/10.1182/blood-2011-01-330738

CLL Trialists' Collaborative Group. (1999). Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. Journal of the National Cancer Institute, 91(10), 861-868.

Comenzo, R. L., & Gertz, M. A. (2002). Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99(12), 4276-4282. https://doi.org/10.1182/blood.v99.12.4276

Comenzo, R. L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V., Landau, H., . . . Merlini, G. (2012). Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia, 26(11), 2317-2325. https://doi.org/10.1038/leu.2012.100

Cook, G., Williams, C., Brown, J. M., Cairns, D. A., Cavenagh, J., Snowden, J. A., . . . Morris, T. C. (2014). High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncology, 15(8), 874-885. https://doi.org/10.1016/s1470-2045(14)70245-1

Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhauser, M., Juliusson, G., . . . Ossenkoppele, G. J. (2012). The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature reviews. Clinical oncology, 9(10), 579-590. https://doi.org/10.1038/nrclinonc.2012.150

Cortelazzo, S., Ferreri, A., Hoelzer, D., & Ponzoni, M. (2017). Lymphoblastic lymphoma. Critical Reviews in Oncology/Hematology, 113, 304-317. https://doi.org/10.1016/j.critrevonc.2017.03.020

Cortes, J., Lomaia, E., Turkina, A., Moiraghi, B., Sutton, M. U., Pavlovsky, C., . . . Deininger, M. (2020). Interim Analysis from the OPTIC Trial - A Dose-Ranging Study of 3 Starting Doses of Ponatinib. Møtepresentasjon på 25th EHA Annual Congress: "Unfolding the future!",  June 11-21, 2020. Hentet fra https://library.ehaweb.org/eha/2020/eha25th/294992/

Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D. W., . . . Brummendorf, T. H. (2018a). Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology, 36(3), 231-237. https://doi.org/10.1200/jco.2017.74.7162

Cortes, J. E., Kim, D. W., Kantarjian, H. M., Brummendorf, T. H., Dyagil, I., Griskevicius, L., . . . Gambacorti-Passerini, C. (2012). Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. Journal of Clinical Oncology, 30(28), 3486-3492. https://doi.org/10.1200/JCO.2011.38.7522

Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2018b). Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 132(4), 393-404. https://doi.org/10.1182/blood-2016-09-739086

Costa, R., Abdulhaq, H., Haq, B., Shadduck, R. K., Latsko, J., Zenati, M., . . . Lister, J. (2011). Activity of azacitidine in chronic myelomonocytic leukemia. Cancer, 117(12), 2690-2696. https://doi.org/10.1002/cncr.25759

Craddock, C., Labopin, M., Robin, M., Finke, J., Chevallier, P., Yakoub-Agha, I., . . . Mohty, M. (2016). Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 101(7), 879-883. https://doi.org/10.3324/haematol.2015.140996

Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., . . . Montserrat, E. (2003). ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England Journal of Medicine, 348(18), 1764-1775. https://doi.org/10.1056/NEJMoa023143

Cross, N. C., White, H. E., Colomer, D., Ehrencrona, H., Foroni, L., Gottardi, E., . . . Hochhaus, A. (2015). Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia, 29(5), 999-1003. https://doi.org/10.1038/leu.2015.29

Cross, N. C., White, H. E., Müller, M. C., Saglio, G., & Hochhaus, A. (2012). Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 26(10), 2172-2175. https://doi.org/10.1038/leu.2012.104

Cusack, J. C., Jr., Seymour, J. F., Lerner, S., Keating, M. J., & Pollock, R. E. (1997). Role of splenectomy in chronic lymphocytic leukemia. Journal of the American College of Surgeons, 185(3), 237-243. https://doi.org/10.1016/s1072-7515(97)00057-4

D'Sa, S., Kersten, M. J., Castillo, J. J., Dimopoulos, M., Kastritis, E., Laane, E., . . . Lunn, M. P. (2017). Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. British Journal of Haematology, 176(5), 728-742. https://doi.org/10.1111/bjh.14492

Damaj, G., Duhamel, A., Robin, M., Beguin, Y., Michallet, M., Mohty, M., . . . Yakoub-Agha, I. (2012). Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. Journal of Clinical Oncology, 30(36), 4533-4540. https://doi.org/10.1200/jco.2012.44.3499

Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., . . . Chiorazzi, N. (1999). Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94(6), 1840-1847. https://doi.org/10.1182/blood.V94.6.1840

Davis, B. H., Holden, J. T., Bene, M. C., Borowitz, M. J., Braylan, R. C., Cornfield, D., . . . Stetler-Stevenson, M. (2007). 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry. Part B, Clinical cytometry, 72 Suppl 1, S5-13. https://doi.org/10.1002/cyto.b.20365

de Botton, S., Fawaz, A., Chevret, S., Dombret, H., Thomas, X., Sanz, M., . . . Fenaux, P. (2005). Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. Journal of Clinical Oncology, 23(1), 120-126. https://doi.org/10.1200/jco.2005.03.127

de la Rubia, J., Regadera, A., Martin, G., Cervera, J., Sanz, G., Martinez, J., . . . Sanz, M. (2002). FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leukemia Research, 26(8), 725-730. https://doi.org/10.1016/s0145-2126(02)00003-6

de Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., . . . Marin, D. (2008). Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. Journal of Clinical Oncology, 26(20), 3358-3363. https://doi.org/10.1200/JCO.2007.15.8154

de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., . . . Kroger, N. (2017). Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 129(13), 1753-1762. https://doi.org/10.1182/blood-2016-06-724500

de Waal, E. G., de Munck, L., Hoogendoorn, M., Woolthuis, G., van der Velden, A., Tromp, Y., . . . Hovenga, S. (2015). Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. British Journal of Haematology, 171(5), 720-725. https://doi.org/10.1111/bjh.13653

Dearden, C., Wade, R., Else, M., Richards, S., Milligan, D., Hamblin, T., & Catovsky, D. (2008). The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood, 111(4), 1820-1826. https://doi.org/10.1182/blood-2007-07-101303

Denzlinger, C., Bowen, D., Benz, D., Gelly, K., Brugger, W., & Kanz, L. (2000). Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. British Journal of Haematology, 108(1), 93-95. https://doi.org/10.1046/j.1365-2141.2000.01825.x

Dimopoulos, M. A., Garcia-Sanz, R., Gavriatopoulou, M., Morel, P., Kyrtsonis, M. C., Michalis, E., . . . Sonneveld, P. (2013). Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 122(19), 3276-3282. https://doi.org/10.1182/blood-2013-05-503862

Dimopoulos, M. A., & Kastritis, E. (2018a). Denosumab for myeloma bone disease: ready for prime time? Lancet Oncology, 19(3), 277-278. https://doi.org/10.1016/s1470-2045(18)30075-5

Dimopoulos, M. A., Lonial, S., Betts, K. A., Chen, C., Zichlin, M. L., Brun, A., . . . Richardson, P. G. (2018b). Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer, 124(20), 4032-4043. https://doi.org/10.1002/cncr.31680

Dimopoulos, M. A., Trotman, J., Tedeschi, A., Matous, J. V., Macdonald, D., Tam, C., . . . Buske, C. (2017). Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, 18(2), 241-250. https://doi.org/10.1016/s1470-2045(16)30632-5

Dispenzieri, A., Dingli, D., Kumar, S. K., Rajkumar, S. V., Lacy, M. Q., Hayman, S., . . . Gertz, M. A. (2010). Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. American journal of hematology, 85(10), 757-759. https://doi.org/10.1002/ajh.21822

Dispenzieri, A., Seenithamby, K., Lacy, M. Q., Kumar, S. K., Buadi, F. K., Hayman, S. R., . . . Gertz, M. A. (2013). Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone marrow transplantation, 48(10), 1302-1307. https://doi.org/10.1038/bmt.2013.53

Dodillet, H., Kreuzer, K. A., Monsef, I., & Skoetz, N. (2017). Thrombopoietin mimetics for patients with myelodysplastic syndromes. The Cochrane database of systematic reviews, 9, CD009883. https://doi.org/10.1002/14651858.CD009883.pub2

Dohner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Buchner, T., Burnett, A. K., . . . European LeukemiaNet. (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115(3), 453-474. https://doi.org/10.1182/blood-2009-07-235358

Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., . . . Dohner, H. (2015). International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood, 126(3), 291-299. https://doi.org/10.1182/blood-2015-01-621664

Dreger, P., Corradini, P., Kimby, E., Michallet, M., Milligan, D., Schetelig, J., . . . Chronic Leukemia Working Party of the Ebmt. (2007). Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia, 21(1), 12-17. https://doi.org/10.1038/sj.leu.2404441

Dreger, P., Dohner, H., Ritgen, M., Bottcher, S., Busch, R., Dietrich, S., . . . German C. L. L. Study Group. (2010). Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 116(14), 2438-2447. https://doi.org/10.1182/blood-2010-03-275420

Duetz, C., Westers, T. M., & van de Loosdrecht, A. A. (2019). Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes. Pathobiology : journal of immunopathology, molecular and cellular biology, 86(1), 14-23. https://doi.org/10.1159/000490727

Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S. M., Cole, D., Grant, C., . . . Wilson, W. H. (2013). Low-intensity therapy in adults with Burkitt's lymphoma. New England Journal of Medicine, 369(20), 1915-1925. https://doi.org/10.1056/NEJMoa1308392

Duong, H. K., Akhtari, M., Ahn, K. W., Hu, Z. H., Popat, U. R., Alyea, I. E. P., . . . Saber, W. (2015a). Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biology of Blood and Marrow Transplantation, 21(2 SUPPL. 1), S30-S31. https://doi.org/10.1016/j.bbmt.2014.11.022

Duong, V. H., Bhatnagar, B., Zandberg, D. P., Vannorsdall, E. J., Tidwell, M. L., Chen, Q., & Baer, M. R. (2015b). Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leukemia and Lymphoma, 56(6), 1718-1722. https://doi.org/10.3109/10428194.2014.966708

Durie, B. G., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., . . . Dispenzieri, A. (2017). Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet, 389(10068), 519-527. https://doi.org/10.1016/s0140-6736(16)31594-x

Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., . . . Bloomfield, C. D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424-447. https://doi.org/10.1182/blood-2016-08-733196

Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., . . . Lichter, P. (2000). Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343(26), 1910-1916. https://doi.org/10.1056/NEJM200012283432602

Eichhorst, B. F., Busch, R., Stilgenbauer, S., Stauch, M., Bergmann, M. A., Ritgen, M., . . . German C. L. L. Study Group. (2009). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood, 114(16), 3382-3391. https://doi.org/10.1182/blood-2009-02-206185

Eichhorst, B. F., Fischer, K., Fink, A. M., Elter, T., Wendtner, C. M., Goede, V., . . . Hallek, M. (2011). Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood, 117(6), 1817-1821. https://doi.org/10.1182/blood-2010-04-282228

Elena, C., Galli, A., Such, E., Meggendorfer, M., Germing, U., Rizzo, E., . . . Cazzola, M. (2016). Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood, 128(10), 1408-1417. https://doi.org/10.1182/blood-2016-05-714030

Else, M., Dearden, C. E., Matutes, E., Forconi, F., Lauria, F., Ahmad, H., . . . Catovsky, D. (2011). Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leukemia and Lymphoma, 52 Suppl 2, 75-78. https://doi.org/10.3109/10428194.2011.568650

Fabarius, A., Leitner, A., Hochhaus, A., Muller, M. C., Hanfstein, B., Haferlach, C., . . . Hehlmann, R. (2011). Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 118(26), 6760-6768. https://doi.org/10.1182/blood-2011-08-373902

Falk, R. H. (2005). Diagnosis and management of the cardiac amyloidoses. Circulation, 112(13), 2047-2060. https://doi.org/10.1161/CIRCULATIONAHA.104.489187

Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., . . . Hellstrom-Lindberg, E. (2011). A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 118(14), 3765-3776. https://doi.org/10.1182/blood-2011-01-330126

Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., . . . International Vidaza High-Risk MDS Survival Study Group. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, 10(3), 223-232. https://doi.org/10.1016/S1470-2045(09)70003-8

Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., . . . Silverman, L. R. (2010). Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology, 28(4), 562-569. https://doi.org/10.1200/Jco.2009.23.8329

Fenaux, P., Santini, V., Spiriti, M. A. A., Giagounidis, A., Schlag, R., Radinoff, A., . . . Platzbecker, U. (2018). A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS. Leukemia, 32(12), 2648-2658. https://doi.org/10.1038/s41375-018-0118-9

Feng, D., Edwards, W. D., Oh, J. K., Chandrasekaran, K., Grogan, M., Martinez, M. W., . . . Klarich, K. W. (2007). Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation, 116(21), 2420-2426. https://doi.org/10.1161/CIRCULATIONAHA.107.697763

Feng, D., Syed, I. S., Martinez, M., Oh, J. K., Jaffe, A. S., Grogan, M., . . . Klarich, K. W. (2009). Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation, 119(18), 2490-2497. https://doi.org/10.1161/CIRCULATIONAHA.108.785014

Fermand, J. P., Bridoux, F., Dispenzieri, A., Jaccard, A., Kyle, R. A., Leung, N., & Merlini, G. (2018). Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, 132(14), 1478-1485. https://doi.org/10.1182/blood-2018-04-839480

Fink, E. C., & Ebert, B. L. (2015). The novel mechanism of lenalidomide activity. Blood, 126(21), 2366-2369. https://doi.org/10.1182/blood-2015-07-567958

Fredly, H., Ersvær, E., Kittang, A. O., Tsykunova, G., Gjertsen, B. T., & Bruserud, O. (2013a). The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical epigenetics, 5(1), 13. https://doi.org/10.1186/1868-7083-5-13

Fredly, H., Gjertsen, B. T., & Bruserud, O. (2013b). Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical epigenetics, 5(1), 12. https://doi.org/10.1186/1868-7083-5-12

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . O'Brien, S. M. (2014). Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 370(11), 997-1007. https://doi.org/10.1056/NEJMoa1315226

Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., . . . Tefferi, A. (2011). DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29(4), 392-397. https://doi.org/10.1200/JCO.2010.32.2446

Gardin, C., Turlure, P., Fagot, T., Thomas, X., Terre, C., Contentin, N., . . . Dombret, H. (2007). Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood, 109(12), 5129-5135. https://doi.org/10.1182/blood-2007-02-069666

Garelius, H. K., Johnston, W. T., Smith, A. G., Park, S., de Swart, L., Fenaux, P., . . . Hellstrom-Lindberg, E. (2017). Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. Journal of internal medicine, 281(3), 284-299. https://doi.org/10.1111/joim.12579

Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci-Bresler, A., . . . Rose, C. (2010). Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia Research, 34(9), 1143-1150. https://doi.org/10.1016/j.leukres.2010.03.009

Gattermann, N., & Rachmilewitz, E. A. (2011). Iron overload in MDS-pathophysiology, diagnosis, and complications. Annals of hematology, 90(1), 1-10. https://doi.org/10.1007/s00277-010-1091-1

Gertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., . . . Grateau, G. (2005). Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. American journal of hematology, 79(4), 319-328. https://doi.org/10.1002/ajh.20381

Geyer, H. L., & Mesa, R. A. (2014). Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood, 124(24), 3529-3537. https://doi.org/10.1182/blood-2014-05-577635

Ghanima, W., Heldal, D., & Tjønnfjord, G. E. (2002). Hårcelleleukemi behandlet med cladribin. Tidsskrift for den Norske legeforening, 122(11), 1094-1097.

Ghazal, H. (2002). Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood, 99(3), 1092-1094. https://doi.org/10.1182/blood.v99.3.1092

Giebel, S., Czyz, A., Ottmann, O., Baron, F., Brissot, E., Ciceri, F., . . . Nagler, A. (2016). Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 122(19), 2941-2951. https://doi.org/10.1002/cncr.30130

Giles, F. J., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Thomas, D., . . . Kantarjian, H. (2007). The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. British Journal of Haematology, 136(4), 624-627. https://doi.org/10.1111/j.1365-2141.2006.06476.x

Girinsky, T., Guillot-Vals, D., Koscielny, S., Cosset, J. M., Ganem, G., Carde, P., . . . Munck, J. N. (2001). A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. International Journal of Radiation Oncology Biology Physics, 51(1), 148-155. https://doi.org/10.1016/s0360-3016(01)01626-1

Girmenia, C., Candoni, A., Delia, M., Latagliata, R., Molteni, A., Oliva, E. N., . . . Musto, P. (2019). Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood reviews, 34, 16-25. https://doi.org/10.1016/j.blre.2018.10.002

Gisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H. M., . . . Petrides, P. E. (2013). Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood, 121(10), 1720-1728. https://doi.org/10.1182/blood-2012-07-443770

Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., . . . Kiladjian, J. J. (2020). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. The Lancet. Haematology, 7(3), e196-e208. https://doi.org/10.1016/s2352-3026(19)30236-4

Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., . . . Hallek, M. (2014). Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. New England Journal of Medicine, 370(12), 1101-1110. https://doi.org/10.1056/NEJMoa1313984

Gowin, K., Jain, T., Kosiorek, H., Tibes, R., Camoriano, J., Palmer, J., & Mesa, R. (2017). Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leukemia Research, 54, 73-77. https://doi.org/10.1016/j.leukres.2017.01.006

Gratwohl, A., Stern, M., Brand, R., Apperley, J., Baldomero, H., de Witte, T., . . . European Group for Blood Marrow Transplantation the European Leukemia Net. (2009). Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer, 115(20), 4715-4726. https://doi.org/10.1002/cncr.24531

Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., . . . Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89(6), 2079-2088.

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., . . . Haase, D. (2012). Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120(12), 2454-2465. https://doi.org/10.1182/blood-2012-03-420489

Gribabis, D. A., Panayiotidis, P., Boussiotis, V. A., Hannoun, C., & Pangalis, G. A. (1994). Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematologica, 91(3), 115-118. https://doi.org/10.1159/000204315

Griffiths, H., Brennan, V., Lea, J., Bunch, C., & Chapel, H. (1989). Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood, 73(2), 366-368.

Guglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., . . . Tefferi, A. (2014). The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 28(9), 1804-1810. https://doi.org/10.1038/leu.2014.76

Guiney, M. J., Liew, K. H., Quong, G. G., & Cooper, I. A. (1989). A study of splenic irradiation in chronic lymphocytic leukemia. International Journal of Radiation Oncology Biology Physics, 16(1), 225-229. https://doi.org/10.1016/0360-3016(89)90035-7

Gupta, N., Kavuru, S., Patel, D., Janson, D., Driscoll, N., Ahmed, S., & Rai, K. R. (2002). Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia, 16(10), 2092-2095. https://doi.org/10.1038/sj.leu.2402676

Gökbuget, N. (2013). How I treat older patients with ALL. Blood, 122(8), 1366-1375. https://doi.org/10.1182/blood-2012-07-379016

Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., . . . Bargou, R. C. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 131(14), 1522-1531. https://doi.org/10.1182/blood-2017-08-798322

Haferlach, C., Rieder, H., Lillington, D. M., Dastugue, N., Hagemeijer, A., Harbott, J., . . . Fonatsch, C. (2007). Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes, chromosomes & cancer, 46(5), 494-499. https://doi.org/10.1002/gcc.20433

Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., . . . Ogawa, S. (2014). Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia, 28(2), 241-247. https://doi.org/10.1038/leu.2013.336

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., . . . Kipps, T. J. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111(12), 5446-5456. https://doi.org/10.1182/blood-2007-06-093906

Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., . . . Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376(9747), 1164-1174. https://doi.org/10.1016/S0140-6736(10)61381-5

Hamblin, T. J. (2006). Autoimmune complications of chronic lymphocytic leukemia. Seminars in Oncology, 33(2), 230-239. https://doi.org/10.1053/j.seminoncol.2006.01.011

Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999). Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94(6), 1848-1854.

Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., . . . Barosi, G. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787-798. https://doi.org/10.1056/NEJMoa1110556

Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., . . . Green, A. R. (2005). Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353(1), 33-45. https://doi.org/10.1056/NEJMoa043800

Harrison, C. N., & Robinson, S. E. (2011). Myeloproliferative disorders in pregnancy. Hematology/oncology clinics of North America, 25(2), 261-275, vii. https://doi.org/10.1016/j.hoc.2011.01.008

Hasselbalch, H. C., & Bjørn, M. E. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(17), 1670. https://doi.org/10.1056/NEJMc1502524

Hasselbalch, H. C., & Holmström, M. O. (2019). Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Seminars in immunopathology, 41(1), 5-19. https://doi.org/10.1007/s00281-018-0700-2

Hastings, R., Howell, R., Betts, D., Porter, S., Haferlach, C., Dastugue, N., & Radford-Weiss, I. (2013). Guidelines and Quality Assurance for Acquired Cytogenetics: a common European framework for quality assessment for banded chromosome studies and molecular cytogenetic investigations of acquired abnormalities. (European cytogeneticist association newsletter No. 31 January 2013). Neuilly, France: European cytogeneticist association. Hentet fra http://www.e-c-a.eu/files/downloads/Guidelines/NL31_Acquired_Guidelines.pdf

Hegde, U. P., Wilson, W. H., White, T., & Cheson, B. D. (2002). Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood, 100(6), 2260-2262.

Heim, S., & Mitelman, F. (red.). (2015). Cancer cytogenetics (4. utg.). Hoboken, N.J: Wiley-Blackwell.

Heinrich-Heine University, Duesseldorf. (2011). Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation [pågående studie] (NCT00795548). Hentet fra https://clinicaltrials.gov/ct2/show/NCT00795548

Hellström-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M., Dybedal, I., . . . Wisloff, F. (2003). A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120(6), 1037-1046. https://doi.org/10.1046/j.1365-2141.2003.04153.x

Helsedirektoratet. (2017a). Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft hos barn (3. utg.). (IS-2586). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/retningslinjer/kreft-hos-barn-handlingsprogram

Helsedirektoratet. (2017b). Seneffekter etter kreftbehandling: faglige råd (rev utg.). (IS-2551). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/rapporter/seneffekter-etter-kreftbehandling/Seneffekter%20etter%20kreftbehandling.pdf

Helsedirektoratet. (2019a). Nasjonalt handlingsprogram for palliasjon i kreftomsorgen:nasjonal faglig retningslinje (rev utg.). (IS-2800). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/tema/palliasjon

Helsedirektoratet. (2019b). Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne lymfomer: nasjonale faglige retningslinjer (rev utg.). (IS-2747). Oslo: Helsedirektoratet. Hentet fra https://www.helsedirektoratet.no/retningslinjer/lymfekreft-handlingsprogram

Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., . . . Mayer, J. (2007). Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 25(35), 5616-5623. https://doi.org/10.1200/Jco.2007.12.9098

Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., . . . Burnett, A. K. (2014). Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncology, 15(9), 986-996. https://doi.org/10.1016/s1470-2045(14)70281-5

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., . . . Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966-984. https://doi.org/10.1038/s41375-020-0776-2

Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., . . . Iris Investigators. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23(6), 1054-1061. https://doi.org/10.1038/leu.2009.38

Hoeks, M., Yu, G., Langemeijer, S., Crouch, S., de Swart, L., Fenaux, P., . . . Smith, A. (2020). Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica, 105(3), 640-651. https://doi.org/10.3324/haematol.2018.212332

Hoelzer, D., Walewski, J., Dohner, H., Viardot, A., Hiddemann, W., Spiekermann, K., . . . Gokbuget, N. (2014). Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 124(26), 3870-3879. https://doi.org/10.1182/blood-2014-03-563627

Hospital, M. A., Viala, K., Dragomir, S., Levy, V., Cohen-Aubart, F., Neil, J., . . . Leblond, V. (2013). Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica, 98(12), e155-157. https://doi.org/10.3324/haematol.2013.087213

Huang, X., Wang, Q., Chen, W., Zeng, C., Chen, Z., Gong, D., . . . Liu, Z. (2014). Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC medicine, 12, 2. https://doi.org/10.1186/1741-7015-12-2

Hughes, T. P., Hochhaus, A., Branford, S., Muller, M. C., Kaeda, J. S., Foroni, L., . . . Iris investigators. (2010). Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 116(19), 3758-3765. https://doi.org/10.1182/blood-2010-03-273979

Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., . . . Kim, D. W. (2019). Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 381(24), 2315-2326. https://doi.org/10.1056/NEJMoa1902328

Huls, G., Chitu, D. A., Havelange, V., Jongen-Lavrencic, M., van de Loosdrecht, A. A., Biemond, B. J., . . . Löwenberg, B. (2019). Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood, 133(13), 1457-1464. https://doi.org/10.1182/blood-2018-10-879866

Hwa, Y. L., Kumar, S. K., Gertz, M. A., Lacy, M. Q., Buadi, F. K., Kourelis, T. V., . . . Dispenzieri, A. (2016). Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American journal of hematology, 91(10), 984-988. https://doi.org/10.1002/ajh.24453

Iland, H. J., Bradstock, K., Supple, S. G., Catalano, A., Collins, M., Hertzberg, M., . . . Seymour, J. F. (2012). All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 120(8), 1570-1580; quiz 1752. https://doi.org/10.1182/blood-2012-02-410746

Itzykson, R., Fenaux, P., Bowen, D., Cross, N. C. P., Cortes, J., De Witte, T., . . . Malcovati, L. (2018). Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. HemaSphere, 2(6), e150. https://doi.org/10.1097/hs9.0000000000000150

Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., . . . Grimwade, D. (2016). Assessment of Minimal Residual Disease in Standard-Risk AML. New England Journal of Medicine, 374(5), 422-433. https://doi.org/10.1056/NEJMoa1507471

Jabbour, E., Kantarjian, H., Ravandi, F., Thomas, D., Huang, X., Faderl, S., . . . O'Brien, S. (2015). Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, 16(15), 1547-1555. https://doi.org/10.1016/s1470-2045(15)00207-7

Jabbour, E., Sasaki, K., Ravandi, F., Huang, X., Short, N. J., Khouri, M., . . . Kantarjian, H. M. (2018). Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer, 124(20), 4044-4055. https://doi.org/10.1002/cncr.31720

Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., . . . Morgan, G. J. (2019). Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 20(1), 57-73. https://doi.org/10.1016/s1470-2045(18)30687-9

Jonas, B. A., & Pollyea, D. A. (2019). How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia, 33(12), 2795-2804. https://doi.org/10.1038/s41375-019-0612-8

Juliusson, G., Heldal, D., Hippe, E., Hedenus, M., Malm, C., Wallman, K., . . . Tjønnfjord, G. (1995). Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. Journal of Clinical Oncology, 13(4), 989-995. https://doi.org/10.1200/JCO.1995.13.4.989

Jurlander, J., Hartmann, G. C., & Hansen, M. M. (1994). Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. European Journal of Haematology, 53(2), 114-118. https://doi.org/10.1111/j.1600-0609.1994.tb01874.x

Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., . . . Mufti, G. J. (2011). TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, 29(15), 1971-1979. https://doi.org/10.1200/jco.2010.31.8576

Jæger, P. H., & Quist-Paulsen, P. (2017). Behandlingsresultater for voksne med akutt lymfoblastisk leuekmi i Norge 2008-2015 [hovedoppgave]. [s.l.]: [s.n.].

Kadia, T. M., Borthakur, G., Garcia-Manero, G., Faderl, S., Jabbour, E., Estrov, Z., . . . Ravandi, F. (2012). Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. British Journal of Haematology, 157(3), 312-320. https://doi.org/10.1111/j.1365-2141.2012.09064.x

Kantarjian, H., Ravandi, F., O'Brien, S., Cortes, J., Faderl, S., Garcia-Manero, G., . . . Freireich, E. J. (2010). Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 116(22), 4422-4429. https://doi.org/10.1182/blood-2010-03-276485

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., . . . Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740-753. https://doi.org/10.1056/NEJMoa1509277

Kantarjian, H. M., Fenaux, P., Sekeres, M. A., Szer, J., Platzbecker, U., Kuendgen, A., . . . Giagounidis, A. (2018). Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. The Lancet. Haematology, 5(3), e117-e126. https://doi.org/10.1016/s2352-3026(18)30016-4

Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., . . . Hochhaus, A. (2012a). Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 119(5), 1123-1129. https://doi.org/10.1182/blood-2011-08-376087

Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., . . . Arthur, C. (2012b). Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology, 30(21), 2670-2677. https://doi.org/10.1200/jco.2011.38.9429

Kastritis, E., Terpos, E., Roussou, M., Gavriatopoulou, M., Pamboukas, C., Boletis, I., . . . Dimopoulos, M. A. (2012). A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 119(23), 5384-5390. https://doi.org/10.1182/blood-2011-12-396903

Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood, 130(7), 900-902. https://doi.org/10.1182/blood-2017-01-763599

Kaufman, J. L., Mina, R., Jakubowiak, A. J., Zimmerman, T. L., Wolf, J. J., Lewis, C., . . . Lonial, S. (2019). Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood cancer journal, 9(1), 3. https://doi.org/10.1038/s41408-018-0154-8

Kelaidi, C., Chevret, S., De Botton, S., Raffoux, E., Guerci, A., Thomas, X., . . . Ades, L. (2009). Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. Journal of Clinical Oncology, 27(16), 2668-2676. https://doi.org/10.1200/jco.2008.18.4119

Kerr, R., Cunningham, J., & Bowen, D. T. (2000). Low-dose melphalan in elderly acute myeloid leukaemia: complete remissions but resistant relapse with therapy-related karyotypes. Leukemia, 14(5), 953. https://doi.org/10.1038/sj.leu.2401762

Kourelis, T. V., Kumar, S. K., Gertz, M. A., Lacy, M. Q., Buadi, F. K., Hayman, S. R., . . . Dispenzieri, A. (2013). Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. Journal of Clinical Oncology, 31(34), 4319-4324. https://doi.org/10.1200/JCO.2013.50.8499

Kröger, N., Iacobelli, S., Franke, G. N., Platzbecker, U., Uddin, R., Hübel, K., . . . de Witte, T. (2017). Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). Journal of Clinical Oncology, 35(19), 2157-2164. https://doi.org/10.1200/jco.2016.70.7349

Kumar, S., Kaufman, J. L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., . . . Touzeau, C. (2017). Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 130(22), 2401-2409. https://doi.org/10.1182/blood-2017-06-788786

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., . . . Avet-Loiseau, H. (2016). International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, 17(8), e328-e346. https://doi.org/10.1016/s1470-2045(16)30206-6

Kumar, S. K., Hayman, S. R., Buadi, F. K., Roy, V., Lacy, M. Q., Gertz, M. A., . . . Dispenzieri, A. (2012). Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 119(21), 4860-4867. https://doi.org/10.1182/blood-2012-01-407791

Kyle, R. A., Linos, A., Beard, C. M., Linke, R. P., Gertz, M. A., O'Fallon, W. M., & Kurland, L. T. (1992). Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 79(7), 1817-1822.

Landau, H., Hassoun, H., Rosenzweig, M. A., Maurer, M., Liu, J., Flombaum, C., . . . Comenzo, R. L. (2013). Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia, 27(4), 823-828. https://doi.org/10.1038/leu.2012.274

Landgren, O., Albitar, M., Ma, W., Abbasi, F., Hayes, R. B., Ghia, P., . . . Caporaso, N. E. (2009). B-cell clones as early markers for chronic lymphocytic leukemia. New England Journal of Medicine, 360(7), 659-667. https://doi.org/10.1056/NEJMoa0806122

Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004). Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350(2), 114-124. https://doi.org/10.1056/NEJMoa035572

Landtblom, A. R., Bower, H., Andersson, T. M., Dickman, P. W., Samuelsson, J., Björkholm, M., . . . Hultcrantz, M. (2018). Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia, 32(10), 2203-2210. https://doi.org/10.1038/s41375-018-0027-y

Laneuville, P. (2018). When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Current treatment options in oncology, 19(3), 15. https://doi.org/10.1007/s11864-018-0532-2

Lavi, N., Horowitz, N. A., & Brenner, B. (2014). An update on the management of hematologic malignancies in pregnancy. Women's health (London, England), 10(3), 255-266. https://doi.org/10.2217/whe.14.17

Leblond, V., Johnson, S., Chevret, S., Copplestone, A., Rule, S., Tournilhac, O., . . . Owen, R. G. (2013). Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. Journal of Clinical Oncology, 31(3), 301-307. https://doi.org/10.1200/JCO.2012.44.7920

Leblond, V., Treon, S. P., & Dimopoulos, M. A. (red.). (2017). Waldenström's Macroglobulinemia. Heidelberg: Springer International Publishing.

Lee, J. H., Kim, H., Joo, Y. D., Lee, W. S., Bae, S. H., Zang, D. Y., . . . Lee, K. H. (2017). Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 35(24), 2754-2763. https://doi.org/10.1200/jco.2017.72.8618

Lee, S. J. (2017). Classification systems for chronic graft-versus-host disease. Blood, 129(1), 30-37. https://doi.org/10.1182/blood-2016-07-686642

Lee, Y. G., Kim, I., Yoon, S. S., Park, S., Cheong, J. W., Min, Y. H., . . . Kim, H. J. (2013). Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology, 161(3), 339-347. https://doi.org/10.1111/bjh.12256

Lian, X. Y., Zhang, Z. H., Deng, Z. Q., He, P. F., Yao, D. M., Xu, Z. J., . . . Qian, J. (2016). Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. PLoS One, 11(11), e0165948. https://doi.org/10.1371/journal.pone.0165948

Lin, G., Dispenzieri, A., Kyle, R., Grogan, M., & Brady, P. A. (2013). Implantable cardioverter defibrillators in patients with cardiac amyloidosis. Journal of cardiovascular electrophysiology, 24(7), 793-798. https://doi.org/10.1111/jce.12123

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., . . . Ebert, B. L. (2017). Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. New England Journal of Medicine, 376(6), 536-547. https://doi.org/10.1056/NEJMoa1611604

Lippert, E., Girodon, F., Hammond, E., Jelinek, J., Reading, N. S., Fehse, B., . . . Hermouet, S. (2009). Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica, 94(1), 38-45. https://doi.org/10.3324/haematol.13486

Liu, H. D., Ahn, K. W., Hu, Z. H., Hamadani, M., Nishihori, T., Wirk, B., . . . Saber, W. (2017). Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 23(5), 767-775. https://doi.org/10.1016/j.bbmt.2017.01.078

Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., . . . Platzbecker, U. (2013). Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England Journal of Medicine, 369(2), 111-121. https://doi.org/10.1056/NEJMoa1300874

Lo-Coco, F., Cimino, G., Breccia, M., Noguera, N. I., Diverio, D., Finolezzi, E., . . . Mandelli, F. (2004). Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 104(7), 1995-1999. https://doi.org/10.1182/blood-2004-04-1550

Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). (2011). LOV-2011-06-24-30.

Lowenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., . . . Swiss Group for Clinical Cancer Research Collaborative Group. (2009). High-dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine, 361(13), 1235-1248. https://doi.org/10.1056/NEJMoa0901409

Luskin, M. R., Lee, J. W., Fernandez, H. F., Abdel-Wahab, O., Bennett, J. M., Ketterling, R. P., . . . Luger, S. M. (2016). Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 127(12), 1551-1558. https://doi.org/10.1182/blood-2015-07-657403

Ly, B., Hammerstrøm, J., Bergheim, J., Dahl, I. M., Grøttum, K. A., & Lødemel, B. (1998). En populasjonsbasert undersøkelse av symptomer, funn, komplikasjoner og behandlingsvalg. Tidsskrift for den Norske legeforening, 118(2), 228-232.

Mahon, F. X., Rea, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., . . . Filmc. (2010). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology, 11(11), 1029-1035. https://doi.org/10.1016/S1470-2045(10)70233-3

Malard, F., & Mohty, M. (2020). Acute lymphoblastic leukaemia. Lancet, 395(10230), 1146-1162. https://doi.org/10.1016/S0140-6736(19)33018-1

Mao, Z., Quintanilla-Martinez, L., Raffeld, M., Richter, M., Krugmann, J., Burek, C., . . . Rosenwald, A. (2007). IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. The American journal of surgical pathology, 31(10), 1605-1614. https://doi.org/10.1097/PAS.0b013e31804bdaf8

Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., . . . Barbui, T. (2013). Cardiovascular events and intensity of treatment in polycythemia vera. New England Journal of Medicine, 368(1), 22-33. https://doi.org/10.1056/NEJMoa1208500

Marin, D., Bazeos, A., Mahon, F. X., Eliasson, L., Milojkovic, D., Bua, M., . . . Khorashad, J. S. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28(14), 2381-2388. https://doi.org/10.1200/Jco.2009.26.3087

Martell, M. P., Atenafu, E. G., Minden, M. D., Schuh, A. C., Yee, K. W., Schimmer, A. D., . . . Brandwein, J. M. (2013). Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. British Journal of Haematology, 163(4), 458-464. https://doi.org/10.1111/bjh.12561

Martin, P. J., Lee, S. J., Przepiorka, D., Horowitz, M. M., Koreth, J., Vogelsang, G. B., . . . Cutler, C. S. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biology of Blood and Marrow Transplantation, 21(8), 1343-1359. https://doi.org/10.1016/j.bbmt.2015.05.004

Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gokbuget, N., Topp, M. S., . . . Stein, A. (2017). Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 35(16), 1795-1802. https://doi.org/10.1200/JCO.2016.69.3531

Masarova, L., Patel, K. P., Newberry, K. J., Cortes, J., Borthakur, G., Konopleva, M., . . . Verstovsek, S. (2017). Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. The Lancet. Haematology, 4(4), e165-e175. https://doi.org/10.1016/s2352-3026(17)30030-3

Mateos, M. V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., . . . San-Miguel, J. (2018). Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine, 378(6), 518-528. https://doi.org/10.1056/NEJMoa1714678

Maude, S. L. (2018). Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clinical advances in hematology & oncology : H&O, 16(10), 664-666.

Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., . . . Frei, E., 3rd. (1994). Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New England Journal of Medicine, 331(14), 896-903. https://doi.org/10.1056/NEJM199410063311402

McBride, A., Lathon, S. C., Boehmer, L., Augustin, K. M., Butler, S. K., & Westervelt, P. (2013). Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy, 33(3), 295-303. https://doi.org/10.1002/phar.1198

McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., . . . Attal, M. (2017). Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology, 35(29), 3279-3289. https://doi.org/10.1200/jco.2017.72.6679

McGowan-Jordan, J., Simons, A., & Schmid, M. (red.). (2016). ISCN 2016: an International System for Human Cytogenomic Nomenclature Basel: Krager.

McMullin, M. F., Wilkins, B. S., & Harrison, C. N. (2016). Management of polycythaemia vera: a critical review of current data. British Journal of Haematology, 172(3), 337-349. https://doi.org/10.1111/bjh.13812

Meloni, G., Diverio, D., Vignetti, M., Avvisati, G., Capria, S., Petti, M. C., . . . Lo Coco, F. (1997). Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood, 90(3), 1321-1325.

Mikhael, J. R., Schuster, S. R., Jimenez-Zepeda, V. H., Bello, N., Spong, J., Reeder, C. B., . . . Fonseca, R. (2012). Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 119(19), 4391-4394. https://doi.org/10.1182/blood-2011-11-390930

Minnema, M. C., Kimby, E., D'Sa, S., Fornecker, L. M., Poulain, S., Snijders, T. J., . . . Treon, S. P. (2017). Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica, 102(1), 43-51. https://doi.org/10.3324/haematol.2016.147728

Mittelman, M., Platzbecker, U., Afanasyev, B., Grosicki, S., Wong, R. S. M., Anagnostopoulos, A., . . . Selleslag, D. (2018). Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. The Lancet. Haematology, 5(1), e34-e43. https://doi.org/10.1016/s2352-3026(17)30228-4

Moignet, A., Hasanali, Z., Zambello, R., Pavan, L., Bareau, B., Tournilhac, O., . . . Lamy, T. (2014). Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia, 28(5), 1134-1136. https://doi.org/10.1038/leu.2013.359

Montalban-Bravo, G., Takahashi, K., & Garcia-Manero, G. (2017). Decitabine in TP53-Mutated AML. New England Journal of Medicine, 376(8), 796-797. https://doi.org/10.1056/NEJMc1616062

Myelodysplastic/myeloproliferative neoplasms I. (2017). S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H. Stein, J. Thiele, & J. W. Vardiman (red.), WHO classification of tumours of haematopoietic and lymphoid tissue (rev. 4. utg., s. 81-96). Lyon: IARC.

Myint, H., Copplestone, J. A., Orchard, J., Craig, V., Curtis, D., Prentice, A. G., & Hamon, M. D. (1995). Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 91(2), 341-344. https://doi.org/10.1111/j.1365-2141.1995.tb05300.x

Müller-Hermelink, H. K., Montserrat, E., Catovsky, D., & Harris, N. L. (2001). Chronic lymphocytic leukemia and small lymphocytic lymphoma. I: E. S. Jaffe, N. L. Harris, H. Stein, & J. W. Vardiman (red.), WHO classification of tumours of haematopoietic and lymphoid tissue (s. 195-196). Lyon: IARC.

Nienhuis, H. L., Bijzet, J., & Hazenberg, B. P. (2016). The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney diseases, 2(1), 10-19. https://doi.org/10.1159/000444206

Nijhof, I. S., Franssen, L. E., Levin, M. D., Bos, G. M. J., Broijl, A., Klein, S. K., . . . van de Donk, N. (2016). Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 128(19), 2297-2306. https://doi.org/10.1182/blood-2016-07-729236

Nilsson-Ehle, H., Birgegard, G., Samuelsson, J., Antunovic, P., Astermark, J., Garelius, H., . . . Hellstrom-Lindberg, E. (2011). Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of >/=120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions. European Journal of Haematology, 87(3), 244-252. https://doi.org/10.1111/j.1600-0609.2011.01654.x

Nordic MDS Group. (2019). Nordic guidelines: germline predisposition to myeloid neoplasms: recommendations for genetic diagnosis, clinical management and follow-up. Stockholm: NMDS. Hentet fra https://www.nmds.org/index.php/guidelines/118-summary-pages-of-nordic-guidelines-germline-predisposition-to-myeloid-neoplasms-recommendations-for-genetic-diagnosis-clinical-management-and-follow-up-version-1-0-may-20th-2019

Oliva, E. N., Alati, C., Santini, V., Poloni, A., Molteni, A., Niscola, P., . . . Latagliata, R. (2017). Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. The Lancet. Haematology, 4(3), e127-e136. https://doi.org/10.1016/s2352-3026(17)30012-1

Omoto, E., Deguchi, S., Takaba, S., Kojima, K., Yano, T., Katayama, Y., . . . Kimura, I. (1996). Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia, 10(4), 609-614.

Osuji, N., Matutes, E., Tjonnfjord, G., Grech, H., Del Giudice, I., Wotherspoon, A., . . . Catovsky, D. (2006). T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. Cancer, 107(3), 570-578. https://doi.org/10.1002/cncr.22032

Owen, R. G., Treon, S. P., Al-Katib, A., Fonseca, R., Greipp, P. R., McMaster, M. L., . . . Dimopoulos, M. A. (2003). Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30(2), 110-115. https://doi.org/10.1053/sonc.2003.50082

Palladini, G., Milani, P., Foli, A., Basset, M., Russo, F., Perlini, S., & Merlini, G. (2017). A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood, 129(15), 2120-2123. https://doi.org/10.1182/blood-2016-12-756528

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., . . . Campbell, P. J. (2016). Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine, 374(23), 2209-2221. https://doi.org/10.1056/NEJMoa1516192

Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., . . . Campbell, P. J. (2013). Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 122(22), 3616-3627; quiz 3699. https://doi.org/10.1182/blood-2013-08-518886

Pardanani, A., Witzig, T. E., Schroeder, G., McElroy, E. A., Fonseca, R., Dispenzieri, A., . . . Rajkumar, S. V. (2003). Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood, 101(3), 827-830. https://doi.org/10.1182/blood-2002-06-1698

Park, S., Greenberg, P., Yucel, A., Farmer, C., O'Neill, F., De Oliveira Brandao, C., & Fenaux, P. (2019). Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. British Journal of Haematology, 184(2), 134-160. https://doi.org/10.1111/bjh.15707

Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., . . . Tefferi, A. (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115(9), 1703-1708. https://doi.org/10.1182/blood-2009-09-245837

Patel, B., Kirkwood, A. A., Dey, A., Marks, D. I., McMillan, A. K., Menne, T. F., . . . Fielding, A. K. (2017). Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia, 31(1), 58-64. https://doi.org/10.1038/leu.2016.219

Patnaik, M. M., Parikh, S. A., Hanson, C. A., & Tefferi, A. (2014). Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. British Journal of Haematology, 165(3), 273-286. https://doi.org/10.1111/bjh.12756

Patnaik, M. M., & Tefferi, A. (2018a). Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. American journal of hematology, 93(6), 824-840. https://doi.org/10.1002/ajh.25104

Patnaik, M. M., Vallapureddy, R., Yalniz, F. F., Hanson, C. A., Ketterling, R. P., Lasho, T. L., . . . Tefferi, A. (2018b). Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. American journal of hematology, 93(1), 65-73. https://doi.org/10.1002/ajh.24939

Pautas, C., Merabet, F., Thomas, X., Raffoux, E., Gardin, C., Corm, S., . . . Castaigne, S. (2010). Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. Journal of Clinical Oncology, 28(5), 808-814. https://doi.org/10.1200/jco.2009.23.2652

Paydas, S. (2016). Management of hemopoietic neoplasias during pregnancy. Critical Reviews in Oncology/Hematology, 104, 52-64. https://doi.org/10.1016/j.critrevonc.2016.05.006

Pepper, C., Majid, A., Lin, T. T., Hewamana, S., Pratt, G., Walewska, R., . . . Fegan, C. (2012). Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British Journal of Haematology, 156(4), 499-507. https://doi.org/10.1111/j.1365-2141.2011.08974.x

Peters, C., Dalle, J. H., Locatelli, F., Poetschger, U., Pichler, H., Sedlacek, P., . . . Bader, P. (2020). Tbi or chemotherapy based conditioning for children and adolescents with all: A prospective randomized multicenter-study forum on behalf of the AIEOP-BFM-ALL-SG, IBFM-SG, intreall-SG and EBMT-PD-WP. Presentasjon på 25th EHA Annual Congress: "Unfolding the future!",  June 11-21, 2020. Hentet fra https://library.ehaweb.org/eha/2020/eha25th/294922/

Pettitt, R., Matutes, E., Dearden, C., Oscier, D., Carruthers, S., Dodd, J., . . . Hillmen, P. (2009). Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17P-) CLL. Haematologica, 94(Suppl 2), 138-139.

Pfeifer, H., Wassmann, B., Bethge, W., Dengler, J., Bornhauser, M., Stadler, M., . . . Gmall Study Group. (2013). Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia, 27(6), 1254-1262. https://doi.org/10.1038/leu.2012.352

Pfeilstöcker, M., Tuechler, H., Sanz, G., Schanz, J., Garcia-Manero, G., Solé, F., . . . Greenberg, P. L. (2016). Time-dependent changes in mortality and transformation risk in MDS. Blood, 128(7), 902-910. https://doi.org/10.1182/blood-2016-02-700054

Pieri, L., Pancrazzi, A., Pacilli, A., Rabuzzi, C., Rotunno, G., Fanelli, T., . . . Vannucchi, A. M. (2015). JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood, 125(21), 3352-3353. https://doi.org/10.1182/blood-2015-01-624536

Platzbecker, U. (2019). Treatment of MDS. Blood, 133(10), 1096-1107. https://doi.org/10.1182/blood-2018-10-844696

Pomerantz, A., Rodriguez-Rodriguez, S., Demichelis-Gomez, R., Barrera-Lumbreras, G., Barrales-Benitez, O., Lopez-Karpovitch, X., & Aguayo-Gonzalez, A. (2016). Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used. Blood research, 51(4), 233-241. https://doi.org/10.5045/br.2016.51.4.233

Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S., Smykla, R., . . . Lee, F. Y. (2008). Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112(4), 1005-1012. https://doi.org/10.1182/blood-2008-02-140665

Porwit, A., van de Loosdrecht, A. A., Bettelheim, P., Brodersen, L. E., Burbury, K., Cremers, E., . . . Bene, M. C. (2014). Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia, 28(9), 1793-1798. https://doi.org/10.1038/leu.2014.191

Potter, V. T., Iacobelli, S., van Biezen, A., Maertens, J., Bourhis, J. H., Passweg, J. R., . . . Kroger, N. (2016). Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 22(9), 1615-1620. https://doi.org/10.1016/j.bbmt.2016.05.026

Quintás-Cardama, A., Abdel-Wahab, O., Manshouri, T., Kilpivaara, O., Cortes, J., Roupie, A. L., . . . Verstovsek, S. (2013). Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood, 122(6), 893-901. https://doi.org/10.1182/blood-2012-07-442012

Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., . . . Verstovsek, S. (2009). Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology, 27(32), 5418-5424. https://doi.org/10.1200/jco.2009.23.6075

Quist-Paulsen, P., Toft, N., Heyman, M., Abrahamsson, J., Griskevicius, L., Hallbook, H., . . . Schmiegelow, K. (2020). T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 34(2), 347-357. https://doi.org/10.1038/s41375-019-0598-2

Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., & Pasternack, B. S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46(2), 219-234.

Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., . . . Miguel, J. F. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, 15(12), e538-548. https://doi.org/10.1016/s1470-2045(14)70442-5

Ramos, N. R., Mo, C. C., Karp, J. E., & Hourigan, C. S. (2015). Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of clinical medicine, 4(4), 665-695. https://doi.org/10.3390/jcm4040665

Randen, U., Troen, G., Tierens, A., Steen, C., Warsame, A., Beiske, K., . . . Delabie, J. (2014). Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica, 99(3), 497-504. https://doi.org/10.3324/haematol.2013.091702

Ravandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., . . . Kantarjian, H. (2009). Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of Clinical Oncology, 27(4), 504-510. https://doi.org/10.1200/jco.2008.18.6130

Ravi, P., Kumar, S. K., Roeker, L., Gonsalves, W., Buadi, F., Lacy, M. Q., . . . Rajkumar, S. V. (2018). Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood cancer journal, 8(12), 116. https://doi.org/10.1038/s41408-018-0140-1

Rawstron, A. C., Bennett, F. L., O'Connor, S. J., Kwok, M., Fenton, J. A., Plummer, M., . . . Hillmen, P. (2008). Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. New England Journal of Medicine, 359(6), 575-583. https://doi.org/10.1056/NEJMoa075290

Reikvam, H., Kittang, A. O., Melve, G., Mosevoll, K. A., Bentsen, P. T., Ersvær, E., . . . Bruserud, O. (2013). Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current cancer drug targets, 13(1), 30-47.

Robak, T., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., . . . Moiseev, S. I. (2010). Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28(10), 1756-1765. https://doi.org/10.1200/JCO.2009.26.4556

Robin, M., & Fenaux, P. (2016). Hypomethylating Agents as Bridging Therapy before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myelomonocytic Leukemia? Biology of Blood and Marrow Transplantation, 22(1), 1-2. https://doi.org/10.1016/j.bbmt.2015.11.004

Rodon, P., Hulin, C., Pegourie, B., Tiab, M., Anglaret, B., Benboubker, L., . . . Moreau, P. (2015). Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica, 100(2), e56-59. https://doi.org/10.3324/haematol.2014.110890

Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., . . . participants of the Mascc Esmo Consensus Conference Copenhagen. (2016). 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology, 27(suppl 5), v119-v133. https://doi.org/10.1093/annonc/mdw270

Roschewski, M., Dunleavy, K., Abramson, J. S., Powell, B. L., Link, B. K., Patel, P., . . . Wilson, W. H. (2020). Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 38(22), 2519-2529. https://doi.org/10.1200/JCO.20.00303

Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., . . . Gaidano, G. (2011). The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood, 117(12), 3391-3401. https://doi.org/10.1182/blood-2010-09-302174

Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., . . . Mahon, F. X. (2014). Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. Journal of Clinical Oncology, 32(5), 424-430. https://doi.org/10.1200/jco.2012.48.5797

Rubinow, A., Skinner, M., & Cohen, A. S. (1981). Digoxin sensitivity in amyloid cardiomyopathy. Circulation, 63(6), 1285-1288. https://doi.org/10.1161/01.cir.63.6.1285

Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grunhagen, U., Losem, C., . . . Brugger, W. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381(9873), 1203-1210. https://doi.org/10.1016/s0140-6736(12)61763-2

Ruutu, T., Volin, L., Beelen, D. W., Trenschel, R., Finke, J., Schnitzler, M., . . . Casper, J. (2011). Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica, 96(9), 1344-1350. https://doi.org/10.3324/haematol.2011.043810

Röllig, C., & Ehninger, G. (2015). How I treat hyperleukocytosis in acute myeloid leukemia. Blood, 125(21), 3246-3252. https://doi.org/10.1182/blood-2014-10-551507

Saber, W., & Horowitz, M. M. (2016). Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology / the Education Program of the American Society of Hematology, 2016(1), 478-484. https://doi.org/10.1182/asheducation-2016.1.478

Sachchithanantham, S., Roussel, M., Palladini, G., Klersy, C., Mahmood, S., Venner, C. P., . . . Wechalekar, A. D. (2016). European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. Journal of Clinical Oncology, 34(17), 2037-2045. https://doi.org/10.1200/jco.2015.63.3123

Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G. J., Kulasekararaj, A., . . . Hellstrom-Lindberg, E. (2014). p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica, 99(6), 1041-1049. https://doi.org/10.3324/haematol.2013.098103

Saini, N., Marin, D., Ledesma, C., Delgado, R., Rondon, G., Popat, U. R., . . . Kebriaei, P. (2020). Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood, 136(15), 1786-1789. https://doi.org/10.1182/blood.2019004685

Sainty, D., Liso, V., Cantu-Rajnoldi, A., Head, D., Mozziconacci, M. J., Arnoulet, C., . . . Flandrin, G. (2000). A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood, 96(4), 1287-1296.

Samra, B., Konopleva, M., Isidori, A., Daver, N., & DiNardo, C. (2020). Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. Frontiers in oncology, 10, 562558. https://doi.org/10.3389/fonc.2020.562558

Sanchorawala, V., Shelton, A. C., Lo, S., Varga, C., Sloan, J. M., & Seldin, D. C. (2016). Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood, 128(8), 1059-1062. https://doi.org/10.1182/blood-2016-04-710822

Sanchorawala, V., Sun, F., Quillen, K., Sloan, J. M., Berk, J. L., & Seldin, D. C. (2015). Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood, 126(20), 2345-2347. https://doi.org/10.1182/blood-2015-08-662726

Santini, V., Prebet, T., Fenaux, P., Gattermann, N., Nilsson, L., Pfeilstöcker, M., . . . List, A. F. (2014). Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research, 38(12), 1381-1391. https://doi.org/10.1016/j.leukres.2014.09.008

Sanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., . . . Lo-Coco, F. (2019). Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 133(15), 1630-1643. https://doi.org/10.1182/blood-2019-01-894980

Sanz, M. A., Labopin, M., Gorin, N. C., de la Rubia, J., Arcese, W., Meloni, G., . . . Rocha, V. (2007). Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone marrow transplantation, 39(8), 461-469. https://doi.org/10.1038/sj.bmt.1705620

Sanz, M. A., & Montesinos, P. (2014). How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood, 123(18), 2777-2782. https://doi.org/10.1182/blood-2013-10-512640

Sarvaria, A., Topp, Z., & Saven, A. (2016). Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia: A Review. JAMA oncology, 2(1), 123-129. https://doi.org/10.1001/jamaoncol.2015.4134

Sasaki, K., Jabbour, E. J., Ravandi, F., Short, N. J., Thomas, D. A., Garcia-Manero, G., . . . Kantarjian, H. M. (2016). Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 122(23), 3650-3656. https://doi.org/10.1002/cncr.30231

Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D. W., Bunjes, D., Schwerdtfeger, R., . . . Hehlmann, R. (2010). Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 115(10), 1880-1885. https://doi.org/10.1182/blood-2009-08-237115

Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., . . . Mahon, F. X. (2018). Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, 19(6), 747-757. https://doi.org/10.1016/s1470-2045(18)30192-x

Schanz, J., Tüchler, H., Solé, F., Mallo, M., Luño, E., Cervera, J., . . . Haase, D. (2012). New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. Journal of Clinical Oncology, 30(8), 820-829. https://doi.org/10.1200/jco.2011.35.6394

Schroeder, T., Rachlis, E., Bug, G., Stelljes, M., Klein, S., Steckel, N. K., . . . Kobbe, G. (2015). Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biology of Blood and Marrow Transplantation, 21(4), 653-660. https://doi.org/10.1016/j.bbmt.2014.12.016

Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly-Smith, L., Delaney, M., . . . Shaz, B. H. (2016). Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of clinical apheresis, 31(3), 149-162. https://doi.org/10.1002/jca.21470

Scott, L. J. (2016). Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia. Drugs, 76(8), 889-900. https://doi.org/10.1007/s40265-016-0585-0

Sekeres, M. A., Elson, P., Kalaycio, M. E., Advani, A. S., Copelan, E. A., Faderl, S., . . . Estey, E. (2009). Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood, 113(1), 28-36. https://doi.org/10.1182/blood-2008-05-157065

Selimoglu-Buet, D., Badaoui, B., Benayoun, E., Toma, A., Fenaux, P., Quesnel, B., . . . Wagner-Ballon, O. (2017). Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood, 130(6), 832-835. https://doi.org/10.1182/blood-2017-04-779579

Seymour, J. F., Cusack, J. D., Lerner, S. A., Pollock, R. E., & Keating, M. J. (1997). Case/control study of the role of splenectomy in chronic lymphocytic leukemia. Journal of Clinical Oncology, 15(1), 52-60. https://doi.org/10.1200/JCO.1997.15.1.52

Shaffer, B. C., Ahn, K. W., Hu, Z. H., Nishihori, T., Malone, A. K., Valcárcel, D., . . . Saber, W. (2016). Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 34(16), 1864-1871. https://doi.org/10.1200/jco.2015.65.0515

Shapiro, R. M., & Lazo-Langner, A. (2018). Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. BMC hematology, 18, 3. https://doi.org/10.1186/s12878-017-0094-8

Shen, Q., Ouyang, J., Tang, G., Jabbour, E. J., Garcia-Manero, G., Routbort, M., . . . Wang, S. A. (2015). Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal of Haematology, 95(2), 168-176. https://doi.org/10.1111/ejh.12477

Sher, T., Fenton, B., Akhtar, A., & Gertz, M. A. (2016). First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood, 128(15), 1987-1989. https://doi.org/10.1182/blood-2016-06-722496

Shimoda, K., Shide, K., Kamezaki, K., Okamura, T., Harada, N., Kinukawa, N., . . . Haradaa, M. (2007). The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. International journal of hematology, 85(4), 338-343. https://doi.org/10.1532/ijh97.06135

Shimoni, A., Labopin, M., Savani, B., Volin, L., Ehninger, G., Kuball, J., . . . Nagler, A. (2016). Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. Journal of hematology & oncology, 9(1), 118. https://doi.org/10.1186/s13045-016-0347-1

Short, N. J., Jabbour, E., Sasaki, K., Patel, K., O'Brien, S. M., Cortes, J. E., . . . Ravandi, F. (2016). Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 128(4), 504-507. https://doi.org/10.1182/blood-2016-03-707562

Siegel, D. S., Dimopoulos, M. A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., . . . Stewart, A. K. (2018). Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 36(8), 728-734. https://doi.org/10.1200/jco.2017.76.5032

Sinisalo, M., Aittoniemi, J., Kayhty, H., & Vilpo, J. (2003). Vaccination against infections in chronic lymphocytic leukemia. Leukemia and Lymphoma, 44(4), 649-652. https://doi.org/10.1080/1042819031000063408

Sivaraj, D., Green, M. M., Kang, Y., Long, G. D., Rizzieri, D. A., Li, Z., . . . Gasparetto, C. (2018). Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood cancer journal, 8(8), 71. https://doi.org/10.1038/s41408-018-0104-5

Solh, M., Solomon, S., Morris, L., Holland, K., & Bashey, A. (2016). Extramedullary acute myelogenous leukemia. Blood reviews, 30(5), 333-339. https://doi.org/10.1016/j.blre.2016.04.001

Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-2863. https://doi.org/10.1182/blood-2012-09-455063

Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005). Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106(8), 2912-2919. https://doi.org/10.1182/blood-2005-05-2004

Soutar, R., Lucraft, H., Jackson, G., Reece, A., Bird, J., Low, E., . . . British Society for Haematology. (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. British Journal of Haematology, 124(6), 717-726. https://doi.org/10.1111/j.1365-2141.2004.04834.x

Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., . . . Martinelli, G. (2011). BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 118(5), 1208-1215. https://doi.org/10.1182/blood-2010-12-326405

Stahl, M., DeVeaux, M., de Witte, T., Neukirchen, J., Sekeres, M. A., Brunner, A. M., . . . Zeidan, A. M. (2018). The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood advances, 2(14), 1765-1772. https://doi.org/10.1182/bloodadvances.2018019414

Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., Garcia-Gutiérrez, V., Hochhaus, A., . . . Clark, R. E. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia, 30(8), 1648-1671. https://doi.org/10.1038/leu.2016.104

Stein, B. L., Oh, S. T., Berenzon, D., Hobbs, G. S., Kremyanskaya, M., Rampal, R. K., . . . Hoffman, R. (2015). Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of Clinical Oncology, 33(33), 3953-3960. https://doi.org/10.1200/JCO.2015.61.6474

Stone, M. J. (2011). Pathogenesis and morbidity of autoantibody syndromes in Waldenstrom's macroglobulinemia. Clinical lymphoma, myeloma & leukemia, 11(1), 157-159. https://doi.org/10.3816/CLML.2011.n.037

Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., . . . Dohner, H. (2017). Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New England Journal of Medicine, 377(5), 454-464. https://doi.org/10.1056/NEJMoa1614359

Such, E., Germing, U., Malcovati, L., Cervera, J., Kuendgen, A., Della Porta, M. G., . . . Sanz, G. (2013). Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 121(15), 3005-3015. https://doi.org/10.1182/blood-2012-08-452938

Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., . . . Vardiman, J. W. (red.). (2017). WHO classification of tumours of haematopoietic and lymphoid tissue (rev. 4. utg.). Lyon: IARC.

Symeonidis, A., van Biezen, A., de Wreede, L., Piciocchi, A., Finke, J., Beelen, D., . . . Kroger, N. (2015). Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 171(2), 239-246. https://doi.org/10.1111/bjh.13576

Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., . . . Wiernik, P. H. (2000). Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood, 95(1), 90-95.

Tangen, J. M., Fløisand, Y., Foss-Abrahamsen, J., Haukås, E., Næss, I. A., & Skjelbakken, T. (2008). Overlevelse hos voksne med akutt myelogen leukemi. Tidsskrift for den Norske legeforening, 128(10), 1164-1167.

Tefferi, A. (2016). Myeloproliferative neoplasms: A decade of discoveries and treatment advances. American journal of hematology, 91(1), 50-58. https://doi.org/10.1002/ajh.24221

Tefferi, A. (2021). Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. American journal of hematology, 96(1), 145-162. https://doi.org/10.1002/ajh.26050

Tefferi, A., & Barbui, T. (2020). Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. American journal of hematology, 95(12), 1599-1613. https://doi.org/10.1002/ajh.26008

Terwijn, M., van Putten, W. L., Kelder, A., van der Velden, V. H., Brooimans, R. A., Pabst, T., . . . Schuurhuis, G. J. (2013). High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of Clinical Oncology, 31(31), 3889-3897. https://doi.org/10.1200/jco.2012.45.9628

Thol, F., Schlenk, R. F., Heuser, M., & Ganser, A. (2015). How I treat refractory and early relapsed acute myeloid leukemia. Blood, 126(3), 319-327. https://doi.org/10.1182/blood-2014-10-551911

Tjønnfjord, G. E., Jønsson, V., Ly, B. E., & Johannesen, T. B. (2012). Familiær forekomst av kronsik lymfatisk leukemi i Norge. Tidsskrift for den Norske legeforening, 132(18), 2060-2063. https://doi.org/10.4045/tidsskr.11.1350

Tobin, G., Thunberg, U., Johnson, A., Thorn, I., Söderberg, O., Hultdin, M., . . . Rosenquist, R. (2002). Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood, 99(6), 2262-2264. https://doi.org/10.1182/blood.v99.6.2262

Toft, N., Birgens, H., Abrahamsson, J., Griskevicius, L., Hallbook, H., Heyman, M., . . . Schmiegelow, K. (2018). Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia, 32(3), 606-615. https://doi.org/10.1038/leu.2017.265

Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., . . . Advani, R. H. (2015a). Ibrutinib in previously treated Waldenstrom's macroglobulinemia. New England Journal of Medicine, 372(15), 1430-1440. https://doi.org/10.1056/NEJMoa1501548

Treon, S. P., Xu, L., & Hunter, Z. (2015b). MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia. New England Journal of Medicine, 373(6), 584-586. https://doi.org/10.1056/NEJMc1506192

Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., . . . Hunter, Z. R. (2012). MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. New England Journal of Medicine, 367(9), 826-833. https://doi.org/10.1056/NEJMoa1200710

Vaezi, M., Bahar, B., Mousavi, A., Yaghmai, M., Kasaeian, A., Souri, M., . . . Ghavamzadeh, A. (2017). Comparison of 60 and 80 mg/m(2) of daunorubicin in induction therapy of acute myeloid leukaemia. Hematological oncology, 35(1), 101-105. https://doi.org/10.1002/hon.2236

Vellenga, E., van, P. W., Ossenkoppele, G. J., Verdonck, L. F., Theobald, M., Cornelissen, J. J., . . . Lowenberg, B. (2011). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood, 118(23), 6037-6042. https://doi.org/10.1182/blood-2011-07-370247

Venner, C. P., Lane, T., Foard, D., Rannigan, L., Gibbs, S. D., Pinney, J. H., . . . Wechalekar, A. D. (2012). Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 119(19), 4387-4390. https://doi.org/10.1182/blood-2011-10-388462

Verger, E., Soret-Dulphy, J., Maslah, N., Roy, L., Rey, J., Ghrieb, Z., . . . Kiladjian, J. J. (2018). Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood cancer journal, 8(10), 94. https://doi.org/10.1038/s41408-018-0133-0

Versluis, J., Labopin, M., Niederwieser, D., Socie, G., Schlenk, R. F., Milpied, N., . . . Mohty, M. (2015). Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia, 29(1), 51-57. https://doi.org/10.1038/leu.2014.164

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., . . . Kantarjian, H. M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366(9), 799-807. https://doi.org/10.1056/NEJMoa1110557

Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., . . . Kiladjian, J. J. (2016). Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 101(7), 821-829. https://doi.org/10.3324/haematol.2016.143644

Vora, A., Goulden, N., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., . . . Wade, R. (2014). Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncology, 15(8), 809-818. https://doi.org/10.1016/s1470-2045(14)70243-8

Voso, M. T., Leone, G., Piciocchi, A., Fianchi, L., Santarone, S., Candoni, A., . . . Sica, S. (2017). Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Annals of Oncology, 28(7), 1547-1553. https://doi.org/10.1093/annonc/mdx154

Wahlin, A., Brinch, L., Hornsten, P., Evensen, S. A., Oberg, G., Simonsson, B., & Hedenus, M. (1997). Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia. European Journal of Haematology, 58(4), 233-240. https://doi.org/10.1111/j.1600-0609.1997.tb01660.x

Wang, Y. L., Vandris, K., Jones, A., Cross, N. C., Christos, P., Adriano, F., & Silver, R. T. (2008). JAK2 Mutations are present in all cases of polycythemia vera. Leukemia, 22(6), 1289. https://doi.org/10.1038/sj.leu.2405047

Wattel, E., Guerci, A., Hecquet, B., Economopoulos, T., Copplestone, A., Mahe, B., . . . Fenaux, P. (1996). A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood, 88(7), 2480-2487.

Wechalekar, A. D., & Whelan, C. (2017). Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood cancer journal, 7(3), e546. https://doi.org/10.1038/bcj.2017.26

Weiss, R. B., Freiman, J., Kweder, S. L., Diehl, L. F., & Byrd, J. C. (1998). Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 16(5), 1885-1889. https://doi.org/10.1200/JCO.1998.16.5.1885

Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O'Laughlin, M., Fulton, R. S., . . . Ley, T. J. (2016). TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 375(21), 2023-2036. https://doi.org/10.1056/NEJMoa1605949

Wermke, M., Eckoldt, J., Götze, K. S., Klein, S. A., Bug, G., de Wreede, L. C., . . . Platzbecker, U. (2018). Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. The Lancet. Haematology, 5(5), e201-e210. https://doi.org/10.1016/s2352-3026(18)30036-x

Wermke, M., Schmidt, A., Middeke, J. M., Sockel, K., von Bonin, M., Schönefeldt, C., . . . Platzbecker, U. (2012). MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(23), 6460-6468. https://doi.org/10.1158/1078-0432.Ccr-12-1683

Westers, T. M., Ireland, R., Kern, W., Alhan, C., Balleisen, J. S., Bettelheim, P., . . . van de Loosdrecht, A. A. (2012). Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia, 26(7), 1730-1741. https://doi.org/10.1038/leu.2012.30

Whittle, A. M., Feyler, S., & Bowen, D. T. (2013). Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy. Leukemia research reports, 2(1), 9-11. https://doi.org/10.1016/j.lrr.2012.10.001

Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., . . . Hx-CD20-406 Study Investigators. (2010). Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28(10), 1749-1755. https://doi.org/10.1200/JCO.2009.25.3187

Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K. A., . . . Keating, M. (2007). Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 109(11), 4679-4685. https://doi.org/10.1182/blood-2005-12-051458

Wisløff, F., Gedde-Dahl, T., Tjønnfjord, G. E., & Holte, H. (red.). (2014). Blodsykdommer (7. utg.). Oslo: Gyldendal.

Wolach, O., & Stone, R. M. (2015). How I treat mixed-phenotype acute leukemia. Blood, 125(16), 2477-2485. https://doi.org/10.1182/blood-2014-10-551465

Wolach, O., & Stone, R. M. (2017). Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Current opinion in hematology, 24(2), 139-145. https://doi.org/10.1097/moh.0000000000000322

Wolf, M. B., Murray, F., Kilk, K., Hillengass, J., Delorme, S., Heiss, C., . . . Weber, M. A. (2014). Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. European journal of radiology, 83(7), 1222-1230. https://doi.org/10.1016/j.ejrad.2014.02.008

Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima-Yamashita, Y., Yoshida, K., . . . Ogawa, S. (2017). Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood, 129(17), 2347-2358. https://doi.org/10.1182/blood-2016-12-754796

Zahid, M. F., Barraco, D., Lasho, T. L., Finke, C., Ketterling, R. P., Gangat, N., . . . Patnaik, M. M. (2017). Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 58(6), 1488-1493. https://doi.org/10.1080/10428194.2016.1243681

Österborg, A., Foa, R., Bezares, R. F., Dearden, C., Dyer, M. J., Geisler, C., . . . Rai, K. R. (2009). Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia, 23(11), 1980-1988. https://doi.org/10.1038/leu.2009.146

Sist faglig oppdatert: 23. desember 2021